# Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

> **NCT02781506** · PHASE2 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **RADIATION:** SAbR

## Key facts

- **NCT ID:** NCT02781506
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-20
- **Primary completion:** 2021-05-24
- **Final completion:** 2021-05-24
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming eligible for this trial and therefore, the trial was terminated.
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02781506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02781506, "Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02781506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*